Income StatementBalance SheetCash FlowSegments
Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals Cash Flow Statement

Operating, investing, and financing cash movements

Alnylam Pharmaceuticals generated $714.9M in operating cash flow over the trailing twelve months. After $71.6M in capital expenditures, free cash flow was $643.3M. Free cash flow increased 9.3% year-over-year. Based on the Q1 2026 filing.

Net Cash From Operating (TTM)$714.9MNet Cash From Investing (TTM)$334.2MNet Cash From Financing (TTM)-$319.5MCapital Expenditures (TTM)$71.6MDepreciation And Amortization Cf (TTM)$54.8MNet Change In Cash (TTM)$690.2M
Latest FilingQ1 2026
Report Date2026-04-30
Market Cap$39.2B
P/E Ratio72.83
ROE71.66%

Supplemental

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
ROU assets obtained - operating leases$0.0$9.8M-$1.3M$3.8M$8.8M$0.0
Income taxes paid$6.2M$3.0M-$1.9M$1.3M—$2.4M
Interest paid$12.3M$68.9M$12.6M$23.9M$113.3M$64.2M
ROU Asset Obtained for Lease Liability$0.0$9.8M-$1.3M$3.8M$8.8M$0.0

Investing

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Capital expenditures$9.1M$9.0M$14.3M$12.1M$23.3M$21.8M
Net cash from investing activities-$52.9M$113.8M-$141.4M$501.1M$0.0-$25.5M
Purchases of investments$486.7M$401.6M$459.6M$208.0M$235.9M$261.6M

Operating

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Change in accounts payable—-$157.7M$184.1M$223.5M—-$176.0M
Change in accounts receivable$59.5M$7.4M$136.9M$399.9M—$110.4M
Change in deferred revenue-$12.8M-$27.3M-$13.1M-$12.5M$0.0-$1.6M
Change in inventories-$849.0K-$6.2M-$11.1M-$5.0M—$3.3M
Change in other assets-$25.3M$32.8M-$6.8M$20.7M$71.0M$6.3M
Other working capital changes-$6.8M-$19.4M-$18.5M$6.4M$0.0$3.0M
Depreciation and amortization$14.2M$14.4M$13.9M$13.8M$13.5M$13.6M
Net gains (losses) on investments-$166.0K-$956.0K-$1.4M$0.0$0.0$0.0
Net cash from operating activities-$94.7M-$120.3M$155.7M$325.1M$163.6M$70.5M
Net income-$83.8M-$18.3M-$66.3M$251.1M$147.2M$206.0M
Non-cash interest expense on liabilities related to the sale of future royalties and development funding$31.8M$59.6M$59.6M$59.6M$59.6M—
Non-cash interest expense on liabilities related to the sale of future royalties and development funding$35.3M$35.0M$36.5M$40.9M—$66.2M
Stock-based compensation$91.6M$56.7M$111.7M$108.2M$71.6M$70.2M

Financing

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Proceeds from liabilities related to the sale of future royalties and development funding$0.0$1.5M$1.5M$1.5M$1.5M—
Other, net—$0.0———-$9.0K
Proceeds from liabilities related to the sale of future royalties and development funding—$0.0———$6.0M
Repayment Of Liabilities Related To The Sale Of Future Royalties And Development Funding$0.0$3.3M———$3.4M
Payment of Deferred Purchase Consideration—$0.0———-$9.0K
Noncontrolling interest transactions and other—$0.0———-$9.0K
Net cash from financing activities$31.0M$46.1M$51.8M-$448.3M—$15.7M
Other financing activities—$0.0———-$9.0K
Noncontrolling Interests Activity and Other—$0.0———-$9.0K
Proceeds from issuance of common stock$36.3M$49.4M$81.2M$77.7M$41.7M$13.2M

Free Cash Flow

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Free cash flow-$103.8M-$129.3M$141.4M$313.0M$140.3M$48.7M

Other

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Effect of exchange rate changes on cash-$17.3M$14.1M$27.5M-$927.0K—-$7.1M
Net increase (decrease) in cash—$53.6M$93.6M$376.9M$166.0M$53.6M
Leased assets obtained in exchange for operating lease liabilities$0.0$9.8M-$1.3M$3.8M$8.8M$0.0